On February 7, Mitsubishi Chemical Group (Japan) announced the sale of its pharmaceutical subsidiary Mitsubishi Tanabe Pharma to US investment fund Bain Capital for about 510 billion Yen (3.36 billion USD), with the aim of restoring its stagnant core chemical business.
 |
| Mitsubishi Chemical Group (Japan) announced the sale of its pharmaceutical subsidiary Mitsubishi Tanabe Pharma to US investment fund Bain Capital for about 3.36 billion USD. (Source: Nikkei Asia) |
Mitsubishi Chemical expects to complete the deal between July and September 2025 and realize a net gain of about 95 billion yen. As a result, the company will separate its pharmaceutical business, which requires costs to expand new drug candidates, and then focus on reviving its chemical business.
Mitsubishi Tanabe Pharma develops drugs for the immune and nervous systems. Mitsubishi Chemical invested about 500 billion yen in 2020 to increase its stake in Mitsubishi Tanabe from about 56% to a wholly owned subsidiary.
The pharmaceutical business accounts for 30% of Mitsubishi Chemical's core operating profit in the fiscal year ending March 2024, but it requires a large investment to boost research and development.
The company has been working to rebuild its core chemicals business, which has suffered from declining earnings and faced challenges in securing funding.
Mitsubishi Chemical has approached foreign funds and other potential buyers of Tanabe Pharma, aiming to raise more than 500 billion yen. In a long-term vision presentation released in November 2024, Mitsubishi Chemical stressed the importance of finding the best partner for its pharmaceutical business.
Source: https://baoquocte.vn/quy-dau-tu-my-mua-lai-cong-ty-duoc-pham-cua-nhat-voi-gia-336-ty-usd-303633.html
Comment (0)